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Background: Drugs effective in Alzheimer-type dementia have been tested in subjects with mild cognitive
impairment (MCI) because these are supposed to have Alzheimer’s disease in the predementia stage.
Objectives: To investigate whether MCI criteria used in these drug trials can accurately diagnose subjects
with predementia Alzheimer’s disease.
Methods: MCI criteria of the Gal-Int 11 study, InDDEx study, ADCS memory impairment study, ampakine
CX 516 study, piracetam study, and Merck rofecoxib study were applied retrospectively in a cohort of 150
non-demented subjects from a memory clinic. Forty two had progressed to Alzheimer type dementia
during a five year follow up period and were considered to have predementia Alzheimer’s disease at
baseline. Outcome measures were the odds ratio, sensitivity, specificity, and positive and negative
predictive value.
Results: The odds ratio of the MCI criteria for predementia Alzheimer’s disease varied between 0.84 and
11. Sensitivity varied between 0.46 and 0.83 and positive predictive value between 0.43 and 0.76. None
of the criteria combined a high sensitivity with a high positive predictive value. Exclusion criteria for
depression led to an increase in positive predictive value and specificity at the cost of sensitivity. In subjects
older than 65 years the positive predictive value was higher than in younger subjects.
Conclusions: The diagnostic accuracy of MCI criteria used in trials for predementia Alzheimer’s disease is
low to moderate. Their use may lead to inclusion of many patients who do not have predementia
Alzheimer’s disease or to exclusion of many who do. Subjects with moderately severe depression should
not be excluded from trials in order not to reduce the sensitivity.
S
ubjects with mild cognitive impairment (MCI) often
suffer from Alzheimer’s disease in the predementia
stage.1 For this reason, people with MCI have been
enrolled in trials with drugs that were effective in patients
with Alzheimer-type dementia. However, previous studies
have shown that not all MCI subjects have predementia
Alzheimer’s disease.2 3 In view of this well recognised
heterogeneity of MCI, it is important to determine the extent
to which drug trials have included subjects with MCI who
indeed had predementia Alzheimer’s disease. Our aim in the
present study was to investigate whether MCI criteria used in
previous and ongoing drug trials could accurately diagnose
subjects with predementia Alzheimer’s disease. We applied
these criteria to a well characterised cohort of MCI patients
whose cognitive outcome after five years of follow up was
known and in whom the presence of predementia
Alzheimer’s disease at baseline could be inferred. We also
investigated how exclusion criteria for depression and
vascular co-morbidity affected the diagnostic accuracy. MCI
trials applied exclusion criteria for depression or vascular
comorbidity because these conditions may cause MCI.
However, depressive symptomatology and vascular comor-
bidity often occur in subjects with predementia Alzheimer’s
disease, and exclusion of these may also decrease the
diagnostic accuracy. Finally, because the prevalence of
predementia Alzheimer’s disease increases with age we
investigated whether the diagnostic accuracy was dependent
on age.
METHODS
Subjects
The diagnostic accuracy of MCI definitions was investigated
retrospectively in a cohort of newly referred consecutive non-
demented patients from the Maastricht Memory Clinic with
no apparent cause for their cognitive impairment such as
cerebrovascular disorders, brain trauma, or severe psychiatric
disorders.4 Subjects were referred to the memory clinic by
general practitioners (70%), psychiatrists (16%), neurologists
(6%), or other physicians (8%). Subjects were reinvestigated
two, five, and 10 years after the baseline visit. For the present
study we selected all subjects older than 50 years who had
been eligible for the five year follow up assessment (n=178).
They were considered to have predementia Alzheimer’s
disease at baseline if they met criteria for Alzheimer-type
dementia during the five year follow up period. Outcome
with respect to cognitive functioning was available for 150
subjects (82.3%). Of these, 42 (28%) had predementia
Alzheimer’s disease at baseline. The group of subjects
without predementia Alzheimer’s disease (n=108) included
one with frontotemporal dementia, one with dementia from
other causes, three with vascular cognitive impairment, and
one with Parkinson’s disease at follow up. Cognitive outcome
was not available for 28 subjects because they had died
(n=5), could not be traced (n=12), had refused follow up
(n=9), or were not contacted for other reasons (n=2).
Subjects without cognitive outcome were older than those
with cognitive outcome (68.3 years v 61.8 years), while sex,
years of education, and scores on the global deterioration
Abbreviations: BDRS, Blessed dementia rating scale; CDR, clinical
demetia rating scale; DSM-IV, Diagnostic and Statistical Manual of
Mental Disorders, 4th edition; Gal-Int-11, galantamine international 11
study; GDS, global deterioration scale; HDRS, Hamilton depression
rating scale; HIS, Hachinski ischaemic scale; InDDEx, investigation into
delay to diagnosis of Alzheimer’s disease with Exelon study; LM, logical
memory test; MCI, mild cognitive impairment; MMSE, mini-mental state
examination; NINCDS-ADRDA, National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association; RAVLT, Rey auditory verbal learning task
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scale (GDS),5 mini-mental state examination (MMSE),6
Hamilton depression rating scale (HDRS),7 and the delayed
recall of the Rey auditory verbal learning task (RAVLT) did
not differ.
Subjects gave informed consent before inclusion in the
study. The study was approved by the medical ethics
committee of the University Hospital Maastricht,
Netherlands.
Clinical assessment and clinical diagnosis at baseline
and follow up
At baseline subjects underwent a standardised assessment
which included a history provided by the patient and a
significant other; a psychiatric, neurological, and physical
examination; clinical rating scales (MMSE,6 GDS,5 HDRS-17
items,7 the Blessed dementia rating scale (BDRS) part I,8 and
the Hachinski ischaemic scale (HIS)9); appropriate laboratory
tests; a neuropsychological assessment; and neuroimaging as
described elsewhere.10 The diagnosis of dementia and
Alzheimer’s disease was made according to the DSM-IV
and NINCDS-ADRDA criteria.11 12 The follow up assessment
consisted of a standardised questionnaire about medical
history and cognitive complaints, the MMSE, the GDS, the
HDRS, the BDRS, and a neuropsychological test protocol.13 14
If a subject declined to come for the follow up assessment, a
telephone interview was conducted. This included a standar-
dised questionnaire about medical history and cognitive
complaints, and the Telephone Interview for Cognitive
Status.15 The diagnosis of dementia and Alzheimer’s disease
at follow up was made by a neuropsychiatrist and a
neuropsychologist who were unaware of the results of the
baseline assessment and who made their diagnosis indepen-
dently of each other. If there was disagreement about the
clinical diagnosis, a consensus meeting was held and if no
agreement was reached the subject was considered not
demented.
Definition of MCI according to criteria from trials
MCI trials were selected from the review by Petersen1 and
included the galantamine international 11 (Gal-Int-11)
study, the investigation into delay to diagnosis of
Alzheimer’s disease with Exelon (InDDEx) study,16 the
Alzheimer’s disease cooperative study–memory impairment
study (ADCS-MIS),17 the ampakine CX 516 study,18 the
piracetam study, and the Merck rofecoxib MCI study.19 20
Table 1 shows the eligibility criteria, inclusion criteria for
MCI, and exclusion criteria for depression and vascular
comorbidity of these studies. The criteria were applied
retrospectively in the subjects from the Maastricht Memory
Clinic. If scales and tests used in the trials had not been used
in the memory clinic we chose equivalent scales or tests if
possible, as described below.
Modification of eligibili ty criteria
We did not apply the requirement in the piracetam study that
subjects should score at least one point above the lowest
possible score on seven of eight tests from a cognitive battery
as we did not use this battery or an equivalent battery.
Modification of MCI inclusion criteria
Instead of a score of 0.5 on the clinical dementia rating scale,
we used a score of 3 on the GDS or a score of 2 on the GDS
together with a score of at least 0.5 on the first eight items of
the BDRS as a measure of functional impairment. Instead of
the New York University (NYU) paragraph test used in the
Gal-Int-11 and InDDEx studies and the logical memory (LM)
test of the Wechsler memory scale used in the ADCS-MIS,
ampakine, and piracetam studies we used a Dutch story recall
test which consists of a 20 item story.21 So that we could use a
similar cut off for the Dutch story recall test, we estimated
the centile score relative to healthy control subjects to which
the cut off scores on the NYU test and LM test corresponded
and used this score as the cut off on the Dutch story recall
Table 1 Elgibility criteria, mild cognitice impairment inclusion criteria, and exclusion criteria for depression and vascular
comorbidity
Study
Eligibility criteria* MCI inclusion criteria Exclusion criteria
Age
(years)
MMSE
score Other
Functional
impairment Test impairment Depression Vascular
Gal-Int-11 .50 – – CDR 0.5 NYU ,11 Moderately severe
depression
–
InDDEx 55 to 85 – – CDR 0.5 NYU ,9 HDRS .12; HDRS item
1.1; DSM-IV major
depression
m-HIS.4
ADCS-MIS 55 to 90 .23 – CDR 0.5 Edu ,8: LM-A ,3 HDRS .12 m-HIS.4
Edu 8–15: LM-A ,5
Edu .15: LM-A ,9
Ampakine 55 to 80 .24 – CDR 0.5 Edu ,8: LM-A ,5 GDS .6 m-HIS.4
Edu 8–15: LM-A ,8
Edu .15: LM-A ,13
Piracetam 50 to 90 – Score of at least one
point above the lowest
possible score on 7 of 8
tests from a cognitive
battery
CDR 0.5 LM immediate recall ,10
or difference immediate
and delayed recall LM .5
HDRS .17 –
Rofecoxib .65 .23 BDRS: score ,4 on sum
items 1–12 and score
on first 8 items all ,1
CDR 0.5 RAVLT summed immediate
recall , 38
HDRS .12 m-HIS.4
*All studies required that the subject was not demented at baseline.
Scale or test was not used in the Maastricht Memory Clinic. An equivalent scale or test was used if possible as described in the text.
BDRS, Blessed dementia rating scale; CDR, clinical demetia rating scale; Edu, years of education; GDS, geriatric depression scale; HDRS, Hamilton depression
rating scale; LM-A, delayed recall score of story A from the logical memory test of the Wechsler memory scale; LM, logical memory test from the Wechsler memory
scale–revised; m-HIS, modified Hachinski ischaemic scale; MMSE, mini-mental state examination; NYU, New York University paragraph recall.
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test. Centile scores of the NYU paragraph test were based on
control subjects from the NYU (Kluger A, personal commu-
nication). The cut off score used in the Gal-Int-11 study
corresponded to a score below the 53rd centile, and the cut
off score used in the InDDEx study to a score below the 31st
centile. As no normative data have been published for story A
of the LM test used in the ADCS-MIS and ampakine studies,
we multiplied the cut off by 2 and calculated centile scores
based on published age norms for story A and story B
together.22
In the ADCS-MIS trial, the centile scores were dependent
on age and education and varied between the 38th and 62nd
centile for subjects with more than 15 years of education,
between the 4th and 24th centile for subjects with 8–15 years
of education, and between the 1st and 10th centile for
subjects with less than 8 years of education. In the ampakine
study, the centile scores were also dependent on age and
education and varied between the 76th and 90th centile for
subjects with more than 15 years of education, between the
24th and 50th centile for subjects with 8–15 years of
education, and between the 4th and 24th centile for subjects
with less than 8 years of education. The cut off on the
immediate recall of the LM test used in the piracetam study
corresponded with a centile score between the 1st and 9th
centile depending on the age of the subject.23 The cut off on
the difference between the immediate recall and delayed
recall of the LM test used in the piracetam trial corresponded
approximately to a score below the 50th centile.23
Modification of exclusion criteria
Instead of a score .6 on the geriatric depression rating scale
we used a score .12 on the HDRS as an exclusion criterion in
the ampakine study. Instead of a score .17 on the HDRS-21
items scale used in the piracetam study, we used a score .17
on the HDRS-17 items scale. The exclusion criterion of
moderately severe depression used in the Gal-Int-11 study
was operationalised as a diagnosis of major depression
according to DSM-IV criteria together with a score on the
HDRS .17.
Missing data
Of the 150 subjects with known cognitive outcome, several
had missing data for one or more tests or rating scales. The
HIS was not available for 27 subjects. As these subjects did
not display major vascular pathology on clinical examination
none of these subjects was excluded. The Dutch story recall
test was not administered to 12 subjects. Subjects with
missing data for this test were not included in the eligible
sample for MCI criteria that made use of this test. Compared
with subjects in whom the Dutch story recall test was
administered, those without this test scored higher on the
HDRS (14.4 v 10.2). Age, sex, educational level, MMSE score,
delayed recall score on the RAVLT, or prevalence of
predementia Alzheimer’s disease did not differ. The number
of subjects who were excluded from the eligible sample
because of missing data for the Dutch story recall test was 12
for the Gal-Int-11 study and piracetam studies, 11 for the
Table 2 Number of subjects meeting eligibility criteria and inclusion and exclusion criteria for mild cognitive impairment
Subjects meeting
eligibility criteria (n)
Subjects meeting MCI
inclusion criteria (n)
Subjects meeting exclusion criteria (n)* Subjects meeting MCI
criteria and exclusion
criteria (n)Depression Vascular comorbidity
Gal-Int 11 138 90 13 (2) – 77
InDDEx 98 57 24 (12) 2 (1) 32
ADCS-MIS 97 41 16 (6) 0 25
Ampakine 90 48 14 (4) 2 (1) 33
Piracetam 138 76 15 (3) – 61
Rofecoxib 41 34 9 (7) 0 25
*Numbers of subjects with predementia Alzheimer’s disease given in brackets.
ADCS-MIS, Alzheimer’s disease cooperative study–memory impairment study; Gal-Int-11, galantamine international study 11; InDDEx, investigation into delay to
diagnosis of Alzheimer’s disease with Exelon; MCI, mild cognitive impairment.
Table 3 Baseline characteristics of subjects according to different definitions of mild cognitive impairment
MCI definition in
Gal-Int-11 study
(n = 77)
MCI definition in
InDDEx study
(n = 32)
MCI definition
in ADCS-MIS
study (n = 25)
MCI definition in
ampakine study
(n = 33)
MCI definition in
piracetam study
(n = 61)
MCI definition in
rofecoxib study
(n = 25)
Age 64.2 (8.4) 66.6 (6.9) 68.2 (6.5) 67.8 (7.0) 64.5 (8.9) 70.9 (4.2)
Male:female (% male) 47:30 (61) 20:12 (63) 17:8 (68) 21:12 (64) 35:26 (57) 18:7 (72)
Years of education 10.2 (3.1) 10.8 (3.4) 11.1 (3.7) 11.0 (3.4) 10.4 (3.3) 10.7 (3.2)
Education (%)*
Low 10 (13) 3 (9) 3 (12) 3 (9) 9 (15) 3 (12)
Middle 60 (78) 24 (75) 17 (68) 24 (73) 46 (75) 19 (76)
High 7 (9) 5 (16) 5 (20) 6 (18) 6 (10) 3 (12)
GDS score 2.7 (0.47) 2.6 (0.50) 2.7 (0.46) 2.7 (0.48) 2.7 (0.44) 2.8 (0.41)
GDS 2 (%) 25 (33) 14 (44) 7 (28) 11 (33) 16 (26) 5 (20)
GDS 3 (%) 52 (67) 18 (56) 18 (72) 22 (67) 45 (74) 20 (80)
HDRS score 8.6 (5.1) 4.7 (3.2) 5.2 (3.7) 5.6 (3.6) 8.6 (5.1) 7.1 (3.5)
m-HIS 1.4 (1.7) 1.0 (1.3) 0.96 (1.3) 1.0 (1.2) 1.3 (1.7) 0.84 (1.1)
MMSE score 27.6 (1.8) 27.1 (1.7) 26.7 (1.2) 27.3 (1.4) 27.3 (1.8) 27.4 (1.4)
Delayed recall AVLT (z score) 21.5 (1.2) 21.7 (1.4) 22.2 (1.1) 22.0 (1.2) 21.7 (1.2) 21.5 (1.1)
Fluency animals (z score) 20.78 (0.83) 20.96 (0.82) 21.1 (0.84) 20.99 (0.82) 20.85 (0.79) 20.91 (0.80)
Subjects with predementia AD (%) 33 (43) 18 (56) 19 (76) 23 (70) 29 (48) 13 (52)
Values are mean (SD) unless specified otherwise.
*Low: less than 8 years of education; middle: 8 to 15 years of education; high: 16 or more years of education.
z score indicates the number of standard deviations from the average of a healthy control population.14 A negative z score indicates a score below the average.
AD, Alzheimer’s disease; ADCS-MIS, Alzheimer’s disease cooperative study-memory impairment study; AVLT, auditory verbal learning task Gal-Int-11,
galantamine international study 11; GDS, global deterioration scale; HDRS, Hamilton depression rating scale; InDDEx, investigation into delay to diagnosis of
Alzheimer’s disease with Exelon; MCI, mild cognitive impairment; m-HIS, modified Hachinski ischaemic scale; MMSE, mini-mental state examination.
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Table 4 Diagnostic accuracy of definitions of mild cognitive impairment for predementia Alzheimer’s disease
MCI definition*
Subjects in group
A/B/C/D (n) OR Sensitivity Specificity PPV NPV
MCI definition of the Gal-Int-11
study
Inclusion criteria only 43/55/5/35 5.4 (2.0 to 15) 0.88 (0.77 to 0.98) 0.44 (0.34 to 0.54) 0.39 (0.29 to 0.49) 0.90 (0.81 to 0.98)
Inclusion and exclusion criteria 54/44/7/33 5.8 (2.3 to 14) 0.83 (0.71 to 0.94) 0.55 (0.45 to 0.65) 0.43 (0.32 to 0.54) 0.89 (0.81 to 0.97)
MCI definition of InDDEx study
Inclusion criteria only 32/27/9/30 4.0 (1.6 to 9.8) 0.77 (0.64 to 0.90) 0.54 (0.42 to 0.67) 0.53 (0.40 to 0.66) 0.78 (0.65 to 0.91)
Inclusion and exclusion criteria 45/14/21/18 2.8 (1.2 to 6.6) 0.46 (0.31 to 0.62) 0.76 (0.65 to 0.87) 0.56 (0.39 to 0.73) 0.68 (0.57 to 0.79)
MCI definition of ADCS-MIS
study
Inclusion criteria only 43/16/13/25 5.2 (2.1 to 12) 0.66 (0.51 to 0.81) 0.73 (0.62 to 0.84) 0.61 (0.46 to 0.76) 0.77 (0.66 to 0.88)
Inclusion and exclusion criteria 53/6/19/19 8.8 (3.1 to 25) 0.50 (0.34 to 0.66) 0.90 (0.82 to 0.98) 0.76 (0.59 to 0.93) 0.74 (0.63 to 0.84)
MCI definition of ampakine study
Inclusion criteria only 36/21/5/28 9.6 (3.2 to 29) 0.85 (0.73 to 0.97) 0.63 (0.51 to 0.76) 0.57 (0.43 to 0.71) 0.88 (0.78 to 0.98)
Inclusion and exclusion criteria 47/10/10/23 11 (3.9 to 30) 0.70 (0.54 to 0.85) 0.82 (0.73 to 0.92) 0.70 (0.54 to 0.85) 0.82 (0.73 to 0.92)
MCI definition of piracetam study
Inclusion criteria 54/44/10/32 4.9 (2.1 to 11.7) 0.80 (0.68 to 0.92) 0.55 (0.45 to 0.65) 0.42 (0.31 to 0.53) 0.87 (0.79 to 0.95)
Inclusion and exclusion criteria 66/32/11/29 5.4 (2.4 to 12) 0.73 (0.59 to 0.86) 0.67 (0.58 to 0.77) 0.48 (0.35 to 0.60) 0.86 (0.78 to 0.94)
MCI definition of rofecoxib study
Inclusion criteria 5/14/2/20 3.6 (0.60 to 21) 0.91 (0.79 to 1.0) 0.26 (0.07 to 0.46) 0.59 (0.42 to 0.75) 0.71 (0.38 to 1.0)
Inclusion and exclusion criteria 7/12/9/13 0.84 (0.23 to 3.0) 0.59 (0.39 to 0.80) 0.37 (0.15 to 0.59) 0.52 (0.32 to 0.74) 0.44 (0.19 to 0.68)
Values are means (95% confidence intervals) unless stated.
*Inclusion criteria refer to criteria for mild cognitive impairment. Exclusion criteria refer to exclusion criteria for depression and vascular comorbidity.
Group A, subjects eligible for the study who did not meet the criteria of the MCI definition and who had no predementia Alzheimer’s disease; group B, subjects
eligible for the study who met criteria of the MCI definition and who had no predementia Alzheimer’s disease; group C, subjects eligible for the study who did not
meet criteria of the MCI definition and who had predementia Alzheimer’s disease; group D, subjects eligible for the study who met criteria of the MCI definition and
who had predementia Alzheimer’s disease.
ADCS-MIS, Alzheimer’s disease cooperative study-memory impairment study; Gal-Int-11, galantamine international study 11; InDDEx, investigation into delay to
diagnosis of Alzheimer’s disease with Exelon; MCI, mild cognitive impairment; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value.
Table 5 Effect of age on diagnostic accuracy of mild cognitive impairment definitions for predementia Alzheimer’s disease
MCI definition
Subjects in group
A/B/C/D (n)* OR Sensitivity Specificity PPV NPV
MCI definition of Gal-Int-11 study
Age 50 to 64 years 47/33/3/6 2.8 (0.66 to 12) 0.67 (0.36 to 0.97) 0.59 (0.48 to 0.70) 0.15 (0.04 to 0.27) 0.94 (0.87 to 1.0)
Age 65 to 85 years 7/11/4/27 4.3 (1.0 to 18) 0.87 (0.75 to 0.99) 0.39 (0.16 to 0.61) 0.71 (0.57 to 0.85) 0.64 (0.35 to 0.92)
MCI definition of InDDEx study
Age 55 to 64 years 32/8/3/5 6.9 (1.4 to 35) 0.63 (0.29 to 0.96) 0.80 (0.68 to 0.93) 0.38 (0.12 to 0.65) 0.92 (0.83 to 1.0)
Age 65 to 85 years 12/6/18/13 1.4 (0.43 to 4.9) 0.42 (0.25 to 0.59) 0.67 (0.45 to 0.88) 0.68 (0.48 to 0.89) 0.40 (0.22 to 0.58)
MCI definition of ADCS-MIS study
Age 55 to 64 years 39/2/3/5 33 (4.3 to 244) 0.63 (0.29 to 0.96) 0.95 (0.89 to 1.0) 0.71 (0.38 to 1.0) 0.93 (0.85 to 1.0)
Age 65 to 85 years 14/4/16/14 3.1 (0.82 to 11) 0.47 (0.29 to 0.65) 0.78 (0.59 to 0.97) 0.78 (0.59 to 0.97) 0.47 (0.29 to 0.65)
MCI definition of ampakine study
Age 55 to 64 years 35/5/3/5 12 (2.1 to 65) 0.63 (0.29 to 0.96) 0.88 (0.77 to 0.98) 0.50 (0.19 to 0.81) 0.92 (0.84 to 1.0)
Age 65 to 85 years 12/5/7/18 6.2 (1.6 to 24) 0.72 (0.54 to 0.90) 0.71 (0.49 to 0.92) 0.78 (0.61 to 0.95) 0.63 (0.41 to 0.85)
MCI definition of piracetam study
Age 55 to 64 years 55/24/4/6 4.7 (1.1 to 20) 0.67 (0.36 to 0.97) 0.70 (0.60 to 0.80) 0.20 (0.06 to 0.34) 0.95 (0.89 to 1.0)
Age 65 to 85 years 10/8/8/23 3.6 (1.1 to 12) 0.74 (0.59 to 0.90) 0.56 (0.33 to 0.79) 0.74 (0.59 to 0.90) 0.56 (0.33 to 0.79)
Values are means (95% confidence intervals) unless stated.
*Group A, subjects eligible for the study who did not meet the criteria of the MCI definition and who had no predementia Alzheimer’s disease; group B, subjects
eligible for the study who met criteria of the MCI definition and who had no predementia Alzheimer’s disease; group C, subjects eligible for the study who did not
meet criteria of the MCI definition and who had predementia Alzheimer’s disease; group D, subjects eligible for the study who met criteria of the MCI definition and
who had predementia Alzheimer’s disease.
ADCS-MIS, Alzheimer’s disease cooperative study-memory impairment study; Gal-Int-11, galantamine international study 11; InDDEx, investigation into delay to
diagnosis of Alzheimer’s disease with Exelon; MCI, mild cognitive impairment; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value.
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InDDEx study, nine for the ADCS-MIS study, and eight for
the ampakine study. The BDRS was not scored in one subject
and this individual was excluded from the eligible sample of
the rofecoxib study.
Statistical analysis
For each MCI definition we first determined the sample that
would be eligible for the study. This sample consisted of all
subjects in the age range of the study who did not meet the
criteria for dementia at baseline. Next we applied the
inclusion criteria for MCI. Then we applied the exclusion
criteria for depression or vascular comorbidity. Three sets of
analyses were performed. First, we calculated the diagnostic
accuracy of the MCI definition using both inclusion criteria
and exclusion criteria in the subjects who were eligible for
the study. Second, we calculated the diagnostic accuracy of
the MCI definition using only inclusion criteria. Third, we
calculated the diagnostic accuracy using both inclusion
criteria and exclusion criteria in a young subgroup (age 50
or 55 to 64) and an old subgroup (age 65 or above). For each
analysis we defined four groups: subjects eligible for the
study without predementia Alzheimer’s disease who did not
meet the criteria of the MCI definition (group A); subjects
eligible for the study without predementia Alzheimer’s
disease who met the criteria of the MCI definition (group
B); subjects eligible for the study with predementia
Alzheimer’s disease who did not meet the criteria of the
MCI definition (group C); and subjects eligible for the study
with predementia Alzheimer’s disease who met the criteria of
the MCI definition (group D). Outcome measures were the
odds ratio ((A*D)/(B*C)), sensitivity (D/(C+D)), specificity
(A/(A+B)), positive predictive value (D/(B+D)), and negative
predictive value (A/(A+C)). Data are presented as means and
95% confidence intervals (CI).
RESULTS
Diagnostic accuracy of MCI definitions
Table 2 shows the number of subjects who were eligible for
the study, the number of eligible subjects who met the
inclusion criteria for MCI, the number of subjects with MCI
who were excluded because of depression or vascular
comorbidity, and the number who met both the MCI
inclusion and exclusion criteria. The baseline characteristics
of subjects meeting inclusion and exclusion criteria is shown
in table 3. The odds ratio, sensitivity, specificity, positive
predictive value, and negative predictive for predementia
Alzheimer’s disease of each of the MCI definitions is shown
in table 4.
Effect of exclusion criteria for depression and
vascular comorbidity on diagnostic accuracy
Table 4 shows that after application of the exclusion criteria
the odds ratios of the the criteria in the Gal-Int-11, ADCS-
MIS, and piracetam studies increased and those of the
criteria in the InDDEx, ampakine, and rofecoxib studies
decreased. The sensitivity and negative predictive value
decreased and the specificity increased for all MCI criteria.
The positive predictive value of all criteria except those in the
rofecoxib study increased.
Effect of age on diagnostic accuracy
The effect of age on diagnostic accuracy of the criteria in the
rofecoxib study was not tested as that study included only
subjects older than 65 years. Table 5 shows the effect of age
on the diagnostic accuracy. The positive predictive value was
higher and the specificity and negative predictive value were
lower in the older than in the younger subgroup for all
criteria. For most criteria, the odds ratio was lower and the
sensitivity higher in the older than in the younger subgroup.
DISCUSSION
MCI criteria used in recent drug trials have a low to moderate
diagnostic accuracy for predementia Alzheimer’s disease.
Application of exclusion criteria for depression and vascular
comorbidity led to an increase in the positive predictive value
and specificity at the cost of the sensitivity. The diagnostic
accuracy of the MCI criteria for predementia Alzheimer’s
disease was dependent on age.
Diagnostic accuracy of MCI criteria for predementia
Alzheimer’s disease
There was marked heterogeneity in diagnostic accuracy for
predementia Alzheimer’s disease between the different MCI
criteria. The highest odds ratios were seen for MCI criteria
from the ampakine study (OR=11) and ADCS-MIS study
(OR=8.8). Nevertheless, these odds ratios are below the
observed minimum for a good diagnostic test (25). The odds
ratios of the other MCI criteria were much lower (between
0.84 and 5.8). The variability in diagnostic accuracy may
depend on the variability in the definition of cognitive
impairment. Although all studies used the same definition of
functional impairment (a score of 0.5 on the CDR), there
were marked differences for the definition of impairment on
memory tests. Memory impairment was defined as a score
below the 53rd centile in the Gal-Int-11 study, below the 31st
centile in the InDDEx study, below the 9th centile in the
ADCS-MIS study (this is the average centile score given the
age and education distribution in our sample), below the 31st
centile in the ampakine study (this is also the average
percentile score given the age and education distribution in
our sample), below the 50th centile in the piracetam study,
and below the 46th centile in the rofecoxib study (the centile
score was estimated from data of healthy subjects older than
65 years from the Maastricht aging study).21 As can be seen in
table 2, studies with a strict cut off score for memory
impairment had a higher positive predictive value than those
with a lenient cut off score. It is remarkable that the InDDEx
and Gal-Int-11 studies used a permissive definition of
memory impairment on the NYU paragraph test, as it has
been shown that the best score on this test to identify
subjects with predementia Alzheimer’s disease among those
with MCI is a score below 6, which is well below the cut off
scores used in InDDEx and Gal-Int-11 studies.24
Effect of exclusion criteria for depression and
vascular comorbidity on diagnostic accuracy
The application of exclusion criteria for depression and
vascular comorbidity led to an increase in the odds ratio for
predementia Alzheimer’s disease (indicating an improvement
in overall diagnostic accuracy) for the MCI criteria of the Gal-
Int-11, ADCS-MIS, ampakine, and piracetam studies, and a
decrease in odds ratio for the MCI criteria of the InDDEx and
rofecoxib studies. The specificity and positive predictive value
typically increased, while the sensitivity and negative
predictive value decreased. These effects mainly reflected
the exclusion criteria for depression because 88–100% of the
excluded subjects were excluded because of depression. The
small number of exclusions because of vascular comorbidity
is probably because we had already excluded at baseline
those subjects in whom the cognitive impairment was
thought to be due to vascular lesions. The decrease in odds
ratio of the MCI criteria of the InDDEx and rofecoxib studies
was probably the result of the relatively large number of
excluded subjects who had predementia Alzheimer’s disease.
The effect of the exclusion criteria on the sensitivity
correlated well with the severity of the threshold for
depression: the fall in sensitivity was low for the MCI criteria
of the Gal-Int-11 and piracetam studies which used an high
threshold for depression and high for the MCI criteria of the
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InDDEx study which used a low threshold. The large effect of
depression cut off on sensitivity is consistent with previous
studies that showed a high prevalence of mild depressive
disorders in subjects with predementia Alzheimer’s dis-
ease.14 25 26
Effect of age on diagnostic accuracy
The positive predictive value was higher in the older than in
the younger age group, which is probably because the
prevalence of predementia Alzheimer’s disease was higher
in the older age group. The odds ratio was higher in the
younger than in the older subgroup for the MCI criteria of the
InDDEx, ADCS-MIS, ampakine, and piracetam studies. One
possible explanation for this observation is that in the
younger subgroup the exclusion criteria for depression more
often excluded subjects without than with predementia
Alzheimer’s disease, while in the older age group the
exclusion criteria for depression more often excluded subjects
with than without predementia Alzheimer’s disease.
Limitations
A limitation of the study is that we defined predementia
Alzheimer’s disease as conversion to Alzheimer’s disease-type
dementia after a five year follow up period, because MCI
subjects may convert to Alzheimer’s disease-type dementia at
longer follow up intervals. Thus we may have made a false
negative diagnosis of predementia Alzheimer’s disease in
some cases, which may have led to an underestimation of the
positive predictive value and to an overestimation of the
negative predictive value. However, the number of misclassi-
fied subjects is likely to be small as preliminary data from the
10 year follow up of a subset of patients indicate that only
10% of the non-demented subjects at the five year follow up
converted to dementia during the next five years.
A second limitation is the relatively small sample size for
several of the MCI definitions and age subgroups. This
reduced statistical power and resulted in large 95% con-
fidence intervals.
Another limitation is that we could not always use the
same tests and rating scales that were used in the trials,
which may limit the comparability of our results with that of
the trials. Baseline characteristics of subjects from the ADCS-
MIS and InDDEx trials suggests that nevertheless we have
included a similar population, because subjects included in
the ADCS-MIS trial had similar scores on the MMSE, GDS,
delayed recall, and verbal fluency as subjects who met criteria
of the ADCS-MIS study in our sample17; and subjects
included in the InDDEx trial had similar scores on the
MMSE and GDS as subjects who met the criteria of the
InDDEx study in our sample (table 1).16 In addition, the
finding that the positive predictive value (which is the same
as the conversion rate) was low for subjects meeting the MCI
criteria of the InDDEx and Rofecoxib studies is consistent
with the fact that the follow up of these studies had to be
extended because of a low conversion rate.1
Another difference between the present study and the
trials is that we selected subjects from a clinical setting at the
time of the baseline assessment, while in the trials subjects
could also have been recruited at follow up assessments and
from other settings (for example, they could have been
recruited by advertisements). This difference in subject
selection may have affected the diagnostic accuracy because
of referral and follow up bias. Nevertheless, the way we
selected subjects is representative of the setting in which
drugs would be prescribed.
Finally, our memory clinic is located at a psychiatry
outpatient clinic and the effect of the exclusion criteria for
depression on diagnostic accuracy may be less in settings in
which the prevalence of depression or the awareness of the
diagnosis is lower.
Implications for interpretation of present and ongoing
trials
The findings may have important implications for the
interpretation of present and ongoing trials. The overall
diagnostic accuracy was low to moderate, which means that
many patients will be treated who do not have predementia
Alzheimer’s disease, or that many patients with predementia
Alzheimer’s disease will not be included. It seems useful to
plan subanalyses in subjects older than 65 years as these are
more likely to have predementia Alzheimer’s disease. For
studies that used a permissive definition of memory
impairment, it seems recommendable to plan analysis in a
subsample of subjects with more severe memory impairment.
Implications for design of future trials
As the use of MCI criteria alone will not lead to an accurate
selection of subjects with predementia Alzheimer’s disease, a
major challenge is to find other ways to identify such
individuals. An alternative approach would be to combine a
number of markers of predementia Alzheimer’s disease such
as age, the MMSE score, degree of functional impairment,
impairment on neuropsychological tests, medial temporal
lobe atrophy, and the apolipoprotein E-e4 allele.4 Another
challenge is to exclude subjects with depression related
cognitive impairment without excluding depressed subjects
with predementia Alzheimer’s disease. One option would be
to exclude only subjects with severe depression, as people
with predementia Alzheimer’s disease typically have mild to
moderate depression and score below 21 on the HDRS.14
Another possibility is to exclude only young depressed
subjects, as people with depression related cognitive impair-
ment are younger than those with predementia Alzheimer’s
disease.14
NOTE ADDED IN PROOF
After submission of the final version we obtained normative
data for story A of the logical memory (LM) test from the
Wechsler memory scale from the Chicago health and aging
project (Bennett D, personal communication). As these
normative data may provide better estimates of the centile
scores than those we used in the paper we have recalculated
the diagnostic accuracy of the MCI definitions of the ADCS-
MIS and ampakine studies using the new data. The cut off
points for story A of the LM test used in the ADCS-MIS study
now corresponded with an age and education corrected
centile score between the 17th and 56th centile (on average,
the 23th centile), and the cut off points used in the ampakine
study with a centile score between the 39th and 63rd centile
(on average, the 45th centile). This indicates that according
to the new normative data the severity of the memory
impairment was less than with the normative data used in
the main text. Thirty two subjects now met the inclusion and
exclusion criteria of the ADCS-MIS study and 44 met the
inclusion and exclusion criteria of the ampakine study. The
odds ratio of the ADCS-MIS MCI definition for predementia
Alzheimer’s disease was 7.5, the sensitivity 0.58, the
specificity 0.83, the positive predictive value 0.69, and the
negative predictive value 0.75. The odds ratio of the
ampakine MCI definition for predementia Alzheimer’s
disease was 3.9, the sensitivity 0.70, the specificity 0.63, the
positive predictive value 0.52, and the negative predictive
value 0.78. The effect of the exclusion criteria on the
diagnostic accuracy of the MCI definition of the ADCS-MIS
study was similar to the effect described in table 4. For the
MCI definition of the ampakine study, however, the odds
ratio decreased after application of the exclusion criteria,
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from 6.8 to 3.9. The odds ratio of the ADCS-MIS MCI
definition for predementia Alzheimer’s disease was 12 for
subjects younger than 65 and 3.4 for those older than 65. The
odds ratio of the ampakine MCI definition for predementia
Alzheimer’s disease was 4.4 for subjects younger than 65 and
1.8 for subjects older than 65.
In conclusion, with the new normative data, the estimates
of the specificity, positive predictive accuracy, and overall
diagnostic accuracy were lower than the estimates based on
the normative data that were used in the main text. This
effect was largest for the MCI definition of the ampakine
study. The use of the new normative data would not change
the conclusions of our paper.
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